Aktienanalyse zu Trupanion Inc (TRUP)TRUPTrupanion Inc

Trupanion, Inc. is a medical insurance provider for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe. The Company operates in two segments, namely, Subscription Business and Other Business. The Subscription Business segment is based on subscription payments related to the Company’s direct-to-consumer products. The Other business segment is focuses on other product offerings, primarily involving the underwriting of policies on behalf of third parties with whom the Company maintains business-to-business relationships. It offers Trupanion, software that is designed to communicate directly with veterinary hospital's practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and marketed under the brand names Furkin and PHI Direct in Canada, and a Trupanion branded product in Germany and Switzerland. It operates in the Financials sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Trupanion Inc is currently priced at $28.12, with a high RSI of 91.244 indicating potential overbought conditions. The forward P/E ratio is extremely high at 1428.57, suggesting that the stock may be overvalued compared to its earnings potential. Despite a recent revenue growth of 11% year-over-year in Q2 2026, the stock has seen a significant decline of 36.11% over the past year. The main risk is the downgrade from Piper Sandler, citing a dual-threat macro environment affecting pet insurance demand.

6 analysts cover TRUP: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 54.40.